Search
Penbutolol
go.drugbank.com/drugs/DB01359ApprovedInvestigationalWithdrawnThis binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. … Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker.
Droxicam
go.drugbank.com/drugs/DB09215ApprovedWithdrawnDroxicam is an oxicam non-steroidal anti-inflammatory drug and a prodrug of [DB00554]. … It is used to reduce pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.
Sulfamethoxazole
go.drugbank.com/drugs/DB01015ApprovedInvestigationalin the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. … [L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps
Mixtures: COTRIM E RATIO 480MG/5ML, EUSAPRIM E SUSPENS F ERWSynonyms: 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamideLanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalIt is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. … Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome
Products: Mytolac 60 mg Injektionslösung in einer Fertigspritze, Mytolac 90 mg Injektionslösung in einer FertigspritzeIdecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003] … [A232563] Multiple myeloma is typically treated with an immunomodulatory agent like [lenalidomide],[A232593] a proteasome inhibitor like [bortezomib], or an anti-CD38 monoclonal antibody like [isatuximab
Tafamidis
go.drugbank.com/drugs/DB11644ApprovedInvestigational[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Ephedrine
go.drugbank.com/drugs/DB01364ApprovedInvestigationalEphedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. … [A193701,A193704,L12975] Ephedrine was granted a type 7 FDA Approval on 29 April 2016.[L12975]
Mixtures: COPHADYL-E COUGH LINCTUSProducts: Ephedrinhydrochlorid Aguettant 3 mg/ml Injektionslösung in FertigspritzePancrelipase lipase
go.drugbank.com/drugs/DB13147ApprovedInvestigational[L2509] The pancrelipase lipase is an enzyme secreted by the pancreas that is responsible for the hydrolysis of dietary fat molecules in the human digestive system. … Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.
Products: Formula C & EHistrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawnAs the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).[L41700] … [L41715] Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021.
Synonyms: 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-Nτ-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamidePolythiazide
go.drugbank.com/drugs/DB01324Approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p826)